Comparative Evaluation of Bioactive Glass (Putty) and Platelet Rich Fibrin in Treating Furcation Defects
Comparative Evaluation of Bioactive Glass (Putty) and Platelet Rich Fibrin in Treating Furcation Defects
复制标题
DOI：
10.1563/aaid-joi-d-16-00023
复制
发表时间：
2016-10-01
影响因子：
1.6
通讯作者：
Kurtzman, Gregori M.
中科院分区：
文献类型：
--
作者：
Biswas, Shriparna;Sambashivaiah, Savita;Kurtzman, Gregori M.
本研究的目的是比较第二代生物活性玻璃油灰生物材料与富血小板纤维蛋白治疗II级分叉缺损。受试者为15名全身健康的患者（10名男性和5名女性，年龄20-50岁，平均年龄38.33岁），根据Glickman分类，患有20个下颌磨牙II类分叉缺损。将20个下颌磨牙根分叉缺损随机分为两组：I组10个，采用生物活性玻璃（NovaBone）植骨腻子材料治疗; II组10个，采用富血小板纤维蛋白（PRF）材料治疗。在研究模型上制造定制的丙烯酸支架，并修剪到牙齿的高度轮廓，作为测量的固定参考点。收集以下测量值：牙龈指数、菌斑指数、垂直探测深度（从牙龈边缘到囊袋底部）、临床附着水平（CEJ到囊袋底部）和分叉受累的水平探测深度（使用支架）。结果显示，两组在召回间隔期的牙龈指数（GI）和菌斑指数（PI）均有所改善。两组的垂直和水平探测深度均总体减少;然而，在第三个月（P值= 0.0004）、第六个月（P值= 0.00001）和第九个月（P值= 0.0004）结束时，Putty组（第一组）的垂直探测深度减少量始终大于PRF组（第二组）。我们的结论是，使用生物活性玻璃骨刺激生物材料产生了上级临床结果，包括与自体血小板浓缩物相比，II类分叉缺损的囊袋深度减少增加。我们研究结果的临床意义包括第二代腻子玻璃生物材料在根分叉缺损中的易用性和上级生物性能。
The aim of this study was to compare a second-generation bioactive glass putty biomaterial against platelet rich fibrin in treating grade II furcation defects. Subjects were 15 systemically healthy patients (10 males and 5 females, ages 20-50 with a mean age of 38.33) with 20 mandibular molar class II furcation defects according to Glickman's classification. The 20 mandibular molar furcation defects were randomly allocated as follows: Group I, 10 furcation defects were treated using bioactive glass (NovaBone) bone graft putty material; Group II, 10 furcation defects were treated using platelet rich fibrin (PRF). Customized acrylic stents were fabricated on study casts and trimmed to the height contour of the teeth to serve as a fixed reference point for measurements. The following measurements were collected: gingival index, plaque index, vertical probing depth (from gingival margin to base of the pocket), clinical attachment level (CEJ to the base of the pocket), and horizontal probing depth of furcation involvement (using stent). Results showed that both groups had improvement in gingival index (GI) and plaque index (PI) at the recall intervals. There was an overall reduction in both vertical and horizontal probing depth in both groups; however, the Putty group (Group I) showed consistently more vertical probing depth reduction than the PRF group (Group II) at the end of third month (P-value = 0.0004), sixth month (P-value = 0.00001), and ninth month (P-value = 0.0004). Our conclusion was that use of bioactive glass osteostimulative biomaterial yields superior clinical results, including increased pocket depth reduction of class II furcation defects as compared to an autologous platelet concentrate. The clinical significance of our findings include the ease of use and superior biologic performance of second-generation putty bioglass biomaterials in furcation defects.